Isavuconazole has pharmacokinetic advantages over voriconazole for invasive mold infections. The mechanism of improved PK predictability of isavuconazole is:
- A Isavuconazole is a prodrug (isavuconazonium sulfate) with linear pharmacokinetics; voriconazole shows non-linear PK because it saturates CYP2C19 enzymes, creating unpredictable variability especially in CYP2C19 polymorphisms ✓
- B Isavuconazole has higher CYP3A4 affinity, ensuring consistent metabolism regardless of CYP2C19 genotype
- C Isavuconazole avoids first-pass metabolism entirely by exclusive biliary excretion without hepatic transformation
- D Isavuconazole is renally excreted unchanged, making its clearance predictable with standard renal dosing adjustments
Explanation
Voriconazole exhibits non-linear (Michaelis-Menten) pharmacokinetics because it saturates its own metabolizing enzyme CYP2C19 at therapeutic doses; minor dose changes produce disproportionate plasma level changes. Additionally, CYP2C19 polymorphisms (poor metabolizers vs. ultra-rapid metabolizers) cause 4–5-fold variation in voriconazole AUC, necessitating therapeutic drug monitoring. Isavuconazole (administered as the water-soluble prodrug isavuconazonium sulfate, cleaved by plasma esterases) has linear pharmacokinetics because it is primarily metabolized by CYP3A4 and CYP3A5 — enzymes that are not substrate-saturated at therapeutic doses — with less impact from CYP2C19 genotype variation. It also lacks voriconazole's visual adverse effects and QTc prolongation.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.